A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Inclusion Criteria: * Has histologically or cytologically confirmed, Stage IIIb - IV NSCLC * Has metastatic disease * Has a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) * Has adequate hematologic function * Has adequate hepatic function * Has adequate renal function * Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation Exclusion Criteria: * Has uncontrolled brain metastases * Has leptomeningeal disease * Has received previous chemotherapy for NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization) * Receiving any other investigational agent(s) * Has a history of treatment with other agents targeting the insulin-like growth factor (IGF) or the epidermal growth factor (EGF) receptor * Has a known allergy / history of hypersensitivity reaction to any of the treatment components * Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range \[fasting glucose \<160 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN) and hemoglobin A1C≤ 7%\] and that they are on a stable dietary or therapeutic regimen for this condition * Has an uncontrolled intercurrent illness * Pregnant or lactating * Has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 3 years * Has superior vena cava syndrome contraindicating hydration * Has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure * Has any National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 3.0 Grade ≥2 peripheral neuropathy * Has significant third space fluid retention, requiring repeated drainage